China Pharma Holdings (CPHI) Cash from Investing Activities (2010 - 2025)
China Pharma Holdings (CPHI) reported Cash from Investing Activities of -$5767.0 for Q4 2025, up 97.89% on a YoY basis from -$2914.3 in Q4 2024, and up 85.79% quarter-over-quarter from -$40598.0 in Q3 2025.
China Pharma Holdings (CPHI) Cash from Investing Activities (2010 - 2025) Analysis & Trends
China Pharma Holdings has reported Cash from Investing Activities for 16 years, with the latest figure at -$5767.0 in Q4 2025.
- For the quarter ending Q4 2025, Cash from Investing Activities rose 97.89% year-over-year to -$5767.0; the trailing twelve-month figure through Dec 2025 stood at -$137251.0 (up 59.1% YoY), and the FY2025 full-year result was -$137251.0, up 52.95% from the prior year.
- Cash from Investing Activities for Q4 2025 stood at -$5767.0, up from -$40598.0 in the prior quarter.
- The five-year high for Cash from Investing Activities was $55964.0 in Q1 2023, with the low at -$415977.0 in Q3 2021.
- Historically, Cash from Investing Activities has averaged -$77337.3 across 5 years, with a median of -$19809.0 in 2021.
- Annual changes were most pronounced in 2023 — Cash from Investing Activities soared 4123.29% — and 2024, when it plunged 5927.21%.
- China Pharma Holdings' Cash from Investing Activities stood at -$7056.0 in 2021, then surged by 486.45% to $27268.0 in 2022, then slumped by 116.6% to -$4527.0 in 2023, then sank by 5927.21% to -$272852.0 in 2024, then soared by 97.89% to -$5767.0 in 2025.
- The last three Cash from Investing Activities figures came in at -$5767.0 (Q4 2025), -$40598.0 (Q3 2025), and -$32562.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 229.00 Mn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | -87.00 Mn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 743.70 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | -506.20 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | -60.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | -2.08 Bn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | -15.45 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 25.99 Mn |
| 10 | China Pharma Holdings | 18.87 Mn | 18.70 Mn | 285,487.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -5,767.00 |
| Dec 31, 2025 | -5,767.00 |
| Sep 30, 2025 | -40,598.00 |
| Sep 30, 2025 | -40,598.00 |
| Jun 30, 2025 | -32,562.00 |
| Jun 30, 2025 | -32,562.00 |
| Mar 31, 2025 | -58,324.00 |
| Mar 31, 2025 | -58,324.00 |
| Dec 31, 2024 | -272,852.00 |
| Dec 31, 2024 | -272,852.00 |
| Sep 30, 2024 | 9,220.00 |
| Sep 30, 2024 | 9,220.00 |
| Dec 31, 2023 | -4,527.00 |
| Dec 31, 2023 | -4,527.00 |
| Sep 30, 2023 | -67,455.00 |
| Sep 30, 2023 | -67,455.00 |
| Jun 30, 2023 | 4,501.00 |
| Jun 30, 2023 | 4,501.00 |
| Mar 31, 2023 | 55,964.00 |
| Mar 31, 2023 | 55,964.00 |